BioSpace News Archive

Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable October 31, 2023 to shareholders of record at the close of business on September 29, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter.

Aadi Bioscience, Inc. today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023 at 8:30 am ET (5:30 am PT) to report second quarter 2023 financial results and provide an operational update.

VivoSense, Inc. (“VivoSense”) is thrilled to announce Colin Bower as our new Chief Executive Officer and a member of our Board of Directors. Bower will succeed Dudley Tabakin, who will work closely with Bower to achieve a seamless transition. Tabakin will continue with VivoSense in his new capacity as Chief Product Officer.

CDR-Life Inc. announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy.

IDEAYA Biosciences, Inc. announced achievement of First-Patient-In for the Amgen-sponsored Phase 1/2 clinical trial evaluating the combination of IDE397, the IDEAYA investigational MAT2A inhibitor, and AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, in patients having tumors with MTAP deletion, with an expansion focus in NSCLC.

Perosphere Technologies, a private medical technologies company focused on developing next-generation coagulation diagnostics, announced the appointment of Michelle Brennan to its Board of Directors.

United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended June 30, 2023.

BeiGene, Ltd., a global biotechnology company, reported financial results from the second quarter of 2023 and business highlights.

SpringWorks Therapeutics, Inc. reported second quarter financial results for the period ended June 30, 2023 and provided an update on recent company developments.

Matinas BioPharma Holdings, Inc. announces that Jerome D. Jabbour, Chief Executive Officer, will hold meetings with institutional investors during the BTIG Virtual Biotechnology Conference 2023 being held August 7-8, 2023.